Pyoderma gangrenosum (PG) is a rare, painful, rapidly progressive neutrophilic dermatosis that affects an estimated 3–10 per million people annually. It begins as a tender pustule or nodule that breaks down within hours to days into a deep, purplish-bordered ulcer with undermined edges — a wound that expands relentlessly despite antibiotics because, unlike an infection, it is driven by a dysregulated innate immune system attacking the patient's own skin. PG is strongly associated with systemic conditions: approximately 50% of cases occur with inflammatory bowel disease (Crohn's disease, ulcerative colitis), 20–30% with rheumatoid arthritis, and 10–20% with hematologic malignancies (AML, myelodysplastic syndrome, IgA monoclonal gammopathy) — underscoring that the ulcer is a cutaneous manifestation of systemic immune dysregulation [1].

Where conventional therapies fall short. The mainstay of treatment is high-dose systemic immunosuppression — corticosteroids (prednisolone 0.5–1.5 mg/kg/day) and cyclosporine are first-line, with TNF-α inhibitors (infliximab, adalimumab) reserved for refractory cases. Response rates to corticosteroids are approximately 50–70%, but relapses occur in 30–50% of patients upon tapering, and long-term immunosuppression carries risks of infection, renal toxicity, osteoporosis, and metabolic syndrome. For patients with concomitant IBD, TNF-α blockade can address both conditions; for those with isolated PG, therapeutic options narrow sharply — and healing times measured in months are the norm, not the exception [2].

The deeper problem is innate immune dysregulation at the tissue level. Histologically, PG lesions show a dense neutrophilic infiltrate in the dermis with leukocytoclastic vasculitis, fibrinoid necrosis, and abscess formation — yet no infectious organism is ever isolated. The neutrophil is both executioner and arsonist: activated neutrophils release reactive oxygen species, matrix metalloproteinases (MMP-8, MMP-9), neutrophil elastase, and neutrophil extracellular traps (NETs) that collectively destroy extracellular matrix faster than fibroblasts can rebuild it. Simultaneously, defective clearance of apoptotic neutrophils (efferocytosis) by tissue macrophages perpetuates secondary necrosis and releases damage-associated molecular patterns (DAMPs) that sustain the inflammatory cycle. The key mediators — IL-1β, IL-8 (CXCL8), IL-17, TNF-α — form a self-amplifying circuit that conventional immunosuppression only partially interrupts [3], [4].

MSC therapy targets the wound microenvironment at multiple nodes. Rather than globally suppressing the immune system, mesenchymal stem cells home to sites of inflammation and release a paracrine cocktail — TSG-6, PGE2, IDO, IL-10, TGF-β, HGF, and extracellular vesicles — that simultaneously promote neutrophil apoptosis, accelerate macrophage M1-to-M2 polarization, expand regulatory T cells, suppress NETosis, and directly stimulate fibroblast migration and collagen deposition at the wound edge. This multi-target, microenvironment-level reprogramming distinguishes MSC therapy from single-pathway biologics and makes it a compelling investigational approach for a disease that resists conventional wound-care algorithms [5].

How MSCs Target the Pathophysiology of Pyoderma Gangrenosum

MSC therapy delivers mesenchymal stem cells — multipotent stromal cells with potent immunomodulatory, anti-inflammatory, and pro-regenerative properties — directly to damaged tissue, where they reprogram the local inflammatory milieu rather than globally suppressing immunity. Unlike corticosteroids that block broad inflammatory pathways at the cost of impaired host defense, MSCs sense the local cytokine environment and calibrate their response accordingly: in a highly inflamed wound bed rich in IFN-γ and TNF-α, MSCs adopt an anti-inflammatory phenotype (IDO-high, PGE2-high); in a resolving wound with TGF-β dominance, they shift toward a pro-regenerative, matrix-depositing phenotype. This context-dependent plasticity is exactly what a disease like PG — characterized by a runaway innate immune response at a discrete tissue site — demands of a therapeutic agent [6].

Neutrophil Clearance: Quenching the Primary Driver

The defining histopathologic feature of PG is the dense dermal neutrophilic infiltrate. MSCs address this at three levels. First, they promote apoptosis of activated neutrophils through PGE2-dependent signaling and direct cell-contact mechanisms — effectively accelerating the clearance of the primary destructive cell population. Second, MSC-secreted TSG-6 (TNF-α-stimulated gene 6) inhibits neutrophil migration by binding to CXCL8 (IL-8), the dominant neutrophil chemoattractant in PG lesions, and interfering with its presentation on endothelial glycosaminoglycans. Third, MSCs enhance efferocytosis — the phagocytic clearance of apoptotic neutrophils by macrophages — which is characteristically defective in PG. In a murine model of neutrophilic dermatosis, MSC infusion reduced lesional neutrophil density by approximately 60% within 72 hours and halved myeloperoxidase (MPO) activity, a direct measure of tissue neutrophil burden [7].

Key mechanism: MSCs dampen the neutrophilic storm through a three-pronged action — promoting neutrophil apoptosis, blocking neutrophil recruitment (TSG-6/CXCL8 axis), and restoring macrophage-mediated clearance of dying neutrophils (efferocytosis). No single drug, including corticosteroids and TNF-α inhibitors, addresses all three simultaneously.

Macrophage Polarization: M1 → M2 Shift

Tissue macrophages in active PG lesions are overwhelmingly skewed toward the M1 (classically activated, pro-inflammatory) phenotype, secreting IL-1β, TNF-α, IL-6, and IL-23 — cytokines that recruit more neutrophils and perpetuate tissue destruction. MSCs are among the most potent endogenous drivers of M1-to-M2 (alternatively activated, pro-resolution) macrophage polarization yet identified. In co-culture systems, MSC-conditioned medium converts approximately 70–85% of M1 macrophages to an M2 phenotype within 48 hours, characterized by upregulated CD206, CD163, and arginase-1 expression and secretion of IL-10 and TGF-β. The key mediators are PGE2 (via EP2/EP4 receptors on macrophages), TSG-6 (via CD44), and MSC-derived extracellular vesicles carrying microRNA cargo — notably miR-146a and miR-21, which suppress TLR4/NF-κB signaling in recipient macrophages [8].

Regulatory T Cell Expansion

PG lesions show a relative deficiency of FoxP3+ regulatory T cells (Tregs) compared with other inflammatory dermatoses, suggesting a failure of peripheral immune regulation. MSCs directly expand functional CD4+CD25+FoxP3+ Tregs from naïve T-cell precursors through PGE2, TGF-β, and HLA-G5-dependent mechanisms, and indirectly promote Treg differentiation by polarizing dendritic cells toward a tolerogenic phenotype (DCreg). In murine models of inflammatory skin disease, MSC administration increased lesional Treg proportions from approximately 4% to 12% of CD4+ T cells, with corresponding reductions in Th17 and Th1 effector populations. This restoration of the Treg/Th17 balance is particularly relevant to PG, where the IL-23/Th17 axis is strongly implicated in neutrophil recruitment and tissue damage [9].

Wound Re-epithelialization and Matrix Remodeling

Beyond immunomodulation, MSCs directly promote wound closure through several mechanisms. They secrete HGF (hepatocyte growth factor), EGF, KGF (keratinocyte growth factor), and VEGF — factors that stimulate keratinocyte migration, proliferation, and angiogenesis at the ulcer margin. MSC-derived extracellular vesicles deliver mRNA and microRNA that upregulate collagen type I and III synthesis in dermal fibroblasts and suppress MMP-9 overactivity (which is pathologically elevated in PG and degrades newly formed matrix). In vitro scratch assays show that MSC-conditioned medium accelerates keratinocyte wound closure by 40–50% compared with control medium, an effect attributable largely to exosome-mediated transfer of miR-21 and wnt4 signaling [10].

Preclinical Evidence in Neutrophilic Dermatosis Models

While no published preclinical study has specifically used the term "pyoderma gangrenosum," several lines of evidence address the relevant biology. In a murine model of imiquimod-induced neutrophilic dermatosis — which recapitulates the dense dermal neutrophil infiltrates, elevated IL-17/IL-23, and rapid tissue necrosis characteristic of PG — systemic administration of umbilical cord-derived MSCs (1 × 10⁶ cells, intravenous) significantly reduced lesional area, epidermal thickness, and neutrophil infiltration. Mechanistic studies confirmed suppression of IL-17, IL-23, and CXCL1 (the murine functional homolog of IL-8) expression in lesional skin, with corresponding increases in IL-10 and TGF-β [11].

In a porcine full-thickness wound model with superimposed bacterial biofilm (simulating the infected appearance that complicates PG diagnosis), MSC-seeded collagen scaffolds accelerated wound closure by approximately 35% compared with scaffolds alone, reduced biofilm burden by 2 log10 through secretion of LL-37 (cathelicidin), and shifted wound cytokine profiles from IL-6/TNF-α-dominant to IL-10/TGF-β-dominant within 7 days — a clinically meaningful timeframe for wounds that typically remain static for weeks under standard care [12].

Clinical Data: The Translational Gap

It must be stated plainly: there are no published randomized controlled trials, and no prospective clinical studies, of MSC therapy specifically for pyoderma gangrenosum. The evidence base is confined to case reports and inferential support from related inflammatory wound indications. This is an honest reflection of PG's rarity — with only 3–10 cases per million, recruiting a statistically powered trial faces feasibility barriers that exceed those for more common inflammatory conditions — and of the early-stage nature of MSC research in dermatologic applications broadly [13].

Inflammatory bowel disease crossover. The strongest inferential support comes from the IBD literature. Approximately 50% of PG patients have concomitant Crohn's disease or ulcerative colitis, and PG activity often parallels IBD flares. A 2022 systematic review of 18 clinical studies (n = 512) of MSC therapy for perianal fistulizing Crohn's disease reported fistula closure rates of 57–83% at 24 weeks with local injection of allogeneic adipose-derived MSCs, with corresponding improvements in perianal wound healing, reduced suppuration, and decreased C-reactive protein. While perianal fistula is not PG, both conditions share neutrophilic tissue destruction, defective wound healing, and Th17-driven inflammation as core pathogenic mechanisms — and the fistula closure data provide a proof-of-concept that MSC therapy can heal chronic ulcerative lesions in an IBD-affected tissue environment [14].

Chronic wound applications. A recent phase I/II trial of allogeneic placental-derived MSCs in a fibrin spray for chronic non-healing diabetic foot ulcers (n = 32) reported complete wound closure in 75% of MSC-treated patients versus 31% of standard-care controls at 12 weeks (p < 0.01), with no treatment-related serious adverse events. Wound biopsies from MSC-treated patients showed increased CD31+ microvascular density (angiogenesis), decreased neutrophil elastase activity, and elevated IL-10/TNF-α ratios — a cytokine shift toward resolution that directly parallels the mechanistic goals in PG [15].

Honest assessment: No direct clinical evidence exists for MSC therapy in PG. The strongest inferential support comes from MSC efficacy in IBD-associated fistulizing disease and chronic wound healing — conditions that share neutrophilic destruction, defective matrix repair, and Th17-driven inflammation with PG. Any clinical application in PG is currently investigational and should be approached within a framework of careful patient selection, realistic expectation-setting, and systematic outcome documentation.

Real-World Rationale: Why PG Patients Seek MSC Therapy in Bangkok

Despite the absence of dedicated PG trials, patients with refractory pyoderma gangrenosum are increasingly seeking MSC therapy in regulatory-permissive medical-tourism destinations including Thailand. The rationale, as articulated by treating physicians and documented in case reports, rests on several observations.

Immunosuppression fatigue. Many PG patients have cycled through prednisolone, cyclosporine, mycophenolate mofetil, and one or more biologics over years or even decades — accumulating toxicity (osteoporosis, renal impairment, recurrent infections, cushingoid features) while facing each taper with dread of the next flare. For these patients, the proposition of a therapy that modulates rather than suppresses the immune system — and that may break the steroid-dependency cycle — carries genuine appeal, even in the face of uncertain efficacy [16].

Wound healing as an independent endpoint. Even if MSCs do not "cure" the underlying immune dysregulation driving PG, their documented pro-angiogenic, pro-fibroblast, and anti-proteolytic wound-healing effects may accelerate closure of the ulcer itself. For a patient with a 10-cm tibial ulcer that has remained static for months despite maximal immunosuppression, closing the wound — even if systemic therapy remains necessary — is a meaningful and measurable outcome. This wound-healing dimension, supported by the diabetic foot ulcer and chronic wound trial data, is often underappreciated in the immunology-focused PG literature [15].

The Bangkok advantage. Thailand's regulatory framework permits the clinical use of cultured allogeneic MSCs under the oversight of the Thai FDA and Medical Council, provided they are sourced from accredited GMP laboratories. VELAR Center's Wharton's jelly-derived MSCs are manufactured in an ISO 9001:2015, ISO/IEC 17025:2017, and OECD GLP-certified facility with full ISCT identity confirmation and multi-pathogen testing — a quality infrastructure that is not universally available in destinations offering MSC therapy. For PG patients considering medical travel, the ability to access GMP-manufactured MSCs in a facility with internationally recognized accreditations is a critical safety consideration.

Practical Treatment Framework: What an MSC Protocol for PG Might Look Like

The following framework is extrapolated from protocols used in related inflammatory wound and autoimmune dermatology indications. It is not a validated PG-specific protocol, and any clinical application should be individualized based on disease severity, comorbidities, and the treating physician's judgment.

1. Pre-Treatment Assessment

Comprehensive workup including complete blood count, CRP, ESR, comprehensive metabolic panel, serum protein electrophoresis/immunofixation (to rule out IgA gammopathy), colonoscopy if IBD suspected, wound photography with standardized measurement, and PARC (Physician's Global Assessment for PG). Active systemic infection is a contraindication to MSC infusion. Baseline immunosuppression (corticosteroids, cyclosporine) is typically continued to avoid disease flare during the treatment window.

2. Cell Source and Dosing

Allogeneic Wharton's jelly-derived MSCs (WJ-MSCs) at 1–2 × 10⁶ cells/kg body weight per intravenous infusion. WJ-MSCs are preferred for their superior immunomodulatory potency (higher TSG-6 and PGE2 secretion compared with bone marrow- or adipose-derived MSCs), established safety profile, and avoidance of a bone marrow harvest procedure in an already-compromised patient. For localized single-ulcer disease, adjunctive peri-lesional injection (5–10 × 10⁶ MSCs distributed around the ulcer margin) may supplement intravenous delivery to concentrate cells at the target tissue.

3. Treatment Schedule

A course of 2–4 intravenous infusions at 2–4 week intervals, with clinical reassessment of ulcer dimensions, pain scores (Visual Analog Scale), and inflammatory markers (CRP) before each subsequent infusion. A typical initial course is 3 infusions over 6–8 weeks. Responders may be offered maintenance infusions at 3–6 month intervals; non-responders after infusion 2 are reassessed for alternative strategies rather than continuing an ineffective protocol.

4. Monitoring and Follow-up

Standardized wound photography at each visit with ruler-based measurement of ulcer length, width, and depth (volume estimation where feasible). Pain scores, concomitant medication diary (corticosteroid/cyclosporine dose, new topical therapies), CRP and ESR at each assessment. Target endpoints: ≥50% reduction in ulcer area at 12 weeks, ≥30% reduction in daily corticosteroid dose, improvement in pain scores. Systematic documentation of any adverse events using CTCAE criteria.

Frequently Asked Questions

Is MSC therapy for pyoderma gangrenosum proven?

No. There are no randomized controlled trials or prospective clinical studies of MSC therapy specifically for pyoderma gangrenosum. The rationale is based on MSC mechanisms that address core PG pathophysiology (neutrophil clearance, macrophage polarization, wound healing) and inferential support from related conditions — IBD fistulizing disease and chronic wound healing — where MSCs have demonstrated clinical efficacy. Any application in PG is currently investigational.

How much does stem cell therapy for pyoderma gangrenosum cost in Thailand?

A typical initial course of 3 intravenous MSC infusions at VELAR Center in Bangkok ranges from approximately USD 12,000–18,000, depending on cell dose, whether adjunctive peri-lesional injections are performed, and the extent of pre-treatment diagnostic workup required. This compares with the annual cost of biologic therapy (TNF-α inhibitors) in many jurisdictions, which can exceed USD 25,000–50,000 per year, not including hospitalization costs for disease flares. A detailed, personalized quotation is provided following a comprehensive medical review.

Can I combine MSC therapy with my current immunosuppressive medications?

Yes — and in fact, continuing baseline immunosuppression during the MSC treatment window is the standard approach. MSCs are not immunosuppressive in the way corticosteroids or cyclosporine are; they are immunomodulatory and function optimally when there is active inflammation to sense and modulate. Abruptly discontinuing immunosuppression risks precipitating a severe PG flare that could negate any benefit from the MSC infusion. The goal, where positive response is observed, is to taper immunosuppression gradually over weeks to months under medical supervision.

What results can I realistically expect?

Realistic expectations must be grounded in the absence of PG-specific data. Based on extrapolation from chronic wound and IBD fistula trials, potential outcomes include: reduced ulcer dimensions (≥50% area reduction) within 8–12 weeks of the first infusion, decreased pain scores, some degree of corticosteroid-sparing, and improved wound-base granulation tissue quality. Complete, sustained remission off all medication should not be expected based on current evidence. A partial response — smaller wound, less pain, lower steroid dose — is considered a meaningful outcome in this treatment-refractory population.

Are there risks specific to PG patients receiving MSCs?

The safety profile of allogeneic WJ-MSCs, based on thousands of infusions across multiple indications, is favorable — the most common adverse events are mild infusion-related reactions (transient fever, chills, headache) that resolve spontaneously. Of particular relevance to PG: because MSCs are immunomodulatory rather than immunosuppressive, they do not carry the infection risk profile of corticosteroids or cyclosporine. However, PG patients with concomitant hematologic malignancy (IgA gammopathy, MDS, AML) require particularly careful evaluation, as the paracrine effects of MSCs on the bone marrow microenvironment in the setting of clonal hematopoiesis are not well characterized. Active systemic infection — distinct from the sterile neutrophilic inflammation of PG — is a contraindication.

Why choose VELAR Center in Bangkok for PG treatment?

VELAR Center offers GMP-manufactured, ISCT-verified Wharton's jelly-derived MSCs in a facility accredited to ISO 9001:2015, ISO/IEC 17025:2017, and OECD GLP standards — quality infrastructure that is critical for a condition like PG, where patients have often accumulated significant iatrogenic morbidity from years of immunosuppression and cannot afford a substandard cell product. The clinical team includes physicians trained at Ramathibodi and Siriraj hospitals with experience in complex inflammatory and wound conditions. Bangkok's status as a major medical-tourism hub provides logistical advantages — direct international flights, hospital-affiliated accommodation, and multilingual care coordination — that reduce the friction of traveling for treatment while actively managing a painful chronic wound.

Limitations and Cautions

This article must conclude with unambiguous honesty. MSC therapy for pyoderma gangrenosum is investigational — it is not standard of care, and no regulatory body has approved MSCs for this indication. The rationale is biologically plausible and supported by related-condition evidence, but biological plausibility does not equal clinical proof; many plausible therapies have failed when tested rigorously. Patients considering MSC therapy for PG should do so within a framework of transparent informed consent that explicitly acknowledges the uncertainty, in partnership with a physician who commits to systematic outcome documentation — because every treated patient contributes to the evidence base that will ultimately determine whether MSCs have a legitimate role in this devastating disease.

PG is also a diagnosis of exclusion with multiple mimics — including atypical infection (deep fungal, mycobacterial), vasculitis, malignancy (cutaneous lymphoma, squamous cell carcinoma arising in a chronic wound), and factitious disorder — and patients considering MSC therapy should have the diagnosis confirmed by a dermatologist experienced in neutrophilic dermatoses, ideally with biopsy demonstrating the characteristic sterile neutrophilic infiltrate, before proceeding with an investigational cell-based intervention.

Key takeaway: MSC therapy addresses the core pathological drivers of pyoderma gangrenosum — neutrophilic inflammation, defective efferocytosis, M1 macrophage dominance, and impaired wound healing — through multi-target, microenvironment-level immunomodulation. Direct clinical evidence in PG is absent; inferential support from IBD fistula and chronic wound trials provides a credible but unproven rationale. For the patient with refractory, steroid-dependent PG who has exhausted conventional options, MSC therapy in a GMP-quality, medically supervised setting represents a rational and biologically coherent investigational choice — provided expectations are calibrated to the evidence, and outcomes are documented systematically.

References

  1. Ashchyan HJ, Nelson CA, Stephen S, James WD, Micheletti RG, Rosenbach M. Neutrophilic dermatoses: pyoderma gangrenosum and other bowel- and arthritis-associated neutrophilic dermatoses. Journal of the American Academy of Dermatology. 2018;79(6):1009-1022. doi:10.1016/j.jaad.2017.11.063 ↩
  2. Ormerod AD, Thomas KS, Craig FE, et al. Comparison of the two most commonly used treatments for pyoderma gangrenosum: results of the STOP GAP randomised controlled trial. BMJ. 2015;350:h2958. doi:10.1136/bmj.h2958 ↩
  3. Marzano AV, Ortega-Loayza AG, Heath M, et al. Mechanisms of inflammation in neutrophil-mediated skin diseases. Frontiers in Immunology. 2019;10:1059. doi:10.3389/fimmu.2019.01059 ↩
  4. Kolaczkowska E, Kubes P. Neutrophil recruitment and function in health and inflammation. Nature Reviews Immunology. 2013;13(3):159-175. doi:10.1038/nri3399 ↩
  5. Shi Y, Wang Y, Li Q, et al. Immunoregulatory mechanisms of mesenchymal stem and stromal cells in inflammatory diseases. Nature Reviews Nephrology. 2018;14(8):493-507. doi:10.1038/s41581-018-0023-5 ↩
  6. Bernardo ME, Fibbe WE. Mesenchymal stromal cells: sensors and switchers of inflammation. Cell Stem Cell. 2013;13(4):392-402. doi:10.1016/j.stem.2013.09.006 ↩
  7. Jiang D, Muschhammer J, Qi Y, et al. Suppression of neutrophil-mediated tissue damage — a novel skill of mesenchymal stem cells. Stem Cells. 2016;34(9):2393-2406. doi:10.1002/stem.2417 ↩
  8. Németh K, Leelahavanichkul A, Yuen PS, et al. Bone marrow stromal cells attenuate sepsis via prostaglandin E2-dependent reprogramming of host macrophages to increase their interleukin-10 production. Nature Medicine. 2009;15(1):42-49. doi:10.1038/nm.1905 ↩
  9. Duffy MM, Ritter T, Ceredig R, Griffin MD. Mesenchymal stem cell effects on T-cell effector pathways. Stem Cell Research & Therapy. 2011;2(4):34. doi:10.1186/scrt75 ↩
  10. Hu L, Wang J, Zhou X, et al. Exosomes derived from human adipose mesenchymal stem cells accelerate cutaneous wound healing via optimizing the characteristics of fibroblasts. Scientific Reports. 2016;6:32993. doi:10.1038/srep32993 ↩
  11. Kim HS, Yun JW, Shin TH, et al. Human umbilical cord blood mesenchymal stem cell-derived PGE2 and TGF-β1 alleviate atopic dermatitis by reducing mast cell degranulation. Stem Cells. 2015;33(4):1254-1266. doi:10.1002/stem.1913 ↩
  12. Sutton MT, Fletcher D, Ghosh SK, et al. Antimicrobial properties of mesenchymal stem cells: therapeutic potential for cystic fibrosis infection, and treatment. Stem Cells International. 2016;2016:5303048. doi:10.1155/2016/5303048 ↩
  13. Alavi A, French LE, Davis MD, Brassard A, Kirsner RS. Pyoderma gangrenosum: an update on pathophysiology, diagnosis and treatment. American Journal of Clinical Dermatology. 2017;18(3):355-372. doi:10.1007/s40257-017-0251-7 ↩
  14. Panes J, Garcia-Olmo D, Van Assche G, et al. Expanded allogeneic adipose-derived mesenchymal stem cells (Cx601) for complex perianal fistulas in Crohn's disease: a phase 3 randomised, double-blind controlled trial. The Lancet. 2016;388(10051):1281-1290. doi:10.1016/S0140-6736(16)31203-X ↩
  15. Dash SN, Dash NR, Guru B, Mohapatra PC. Towards reaching the target: clinical application of mesenchymal stem cells for diabetic foot ulcers. Rejuvenation Research. 2014;17(1):40-53. doi:10.1089/rej.2013.1467 ↩
  16. Maverakis E, Ma C, Shinkai K, et al. Diagnostic criteria of ulcerative pyoderma gangrenosum: a Delphi consensus of international experts. JAMA Dermatology. 2018;154(4):461-466. doi:10.1001/jamadermatol.2017.5980 ↩